Tag Archives: finance

Hot Investor Mandate: Private Investment Firm Invests in Seed to Series A Medical Devices, Diagnostics, and Digital Health Companies in North America

4 Nov

An investment firm headquartered in the US focuses on healthcare companies across the seed, venture, and growth stages. The firm typically provides seed and Series A equity financing ranging from $100K to $1M per portfolio company. While the firm often acts as a lead investor, it is also open to participating in syndicated rounds. The firm is open to investment opportunities throughout North America. The firm is actively seeking new investments. 

Current areas of interest include medical devices, diagnostics, digital health, and healthcare-focused software. The firm is also open to reformulated or repurposed drugs, particularly those with reduced development risk. In the medical device category, the firm remains opportunistic across subsectors, with a preference for products that have a prototype and follow the 510(k) regulatory pathway. The firm is indication-agnostic, with interest that includes orphan diseases and the dental field. 

The firm places a strong emphasis on working with experienced management teams and may take a board seat when appropriate. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Europe-Based VC Firm Invests in Early-Stage Companies in Tech-Enabled Life Science and Healthcare Companies

4 Nov

 
This growth-focused investment firm is headquartered in Europe, and was founded by entrepreneurs who previously built and exited a unicorn multinational company. With a renewed mission to drive innovation and growth, the firm targets both early-stage life science ventures and established professional service providers. 

In the early-stage segment, the firm typically invests up to €500K in Series A rounds and makes smaller allocations at the Seed stage. The investment strategy centers on innovative, tech-enabled, and service-oriented companies within the life sciences and healthcare sectors. While the firm is open to early-stage opportunities, it prefers companies with a proven business model and a clear path to scale. 

The firm is eager to partner with strong management teams developing solutions that address unmet needs with a compelling value proposition. Most investments are made as part of a syndicate with institutional venture capital firms, and the firm contributes beyond capital by offering deep sector expertise, an extensive network, and a strong entrepreneurial track record. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

ApexBrasil and ABIQUIFI Deepen Strategic Alliance with Life Science Nation to Globalize Brazil’s Life Science Ecosystem and Leveraging the RESI JPM January Event 

28 Oct

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

São Paulo – Boston | October 2025

Brazil is taking a significant step toward global integration in the life sciences. Last week, ApexBrasil (the Brazilian Trade and Investment Promotion Agency) and ABIQUIFI (the Brazilian Association of Pharmaceutical Inputs Industry) hosted Life Science Nation (LSN) and Ganesha Labs in São Paulo for a week of meetings, workshops, and strategic dialogues with key stakeholders from across the national innovation and investment landscape. 

The visit culminated during the Corporate Venture in Brasil 2025 Conference, held in São Paulo and co-hosted by ApexBrasil, which gathered leading investors, corporate venture leaders, development agencies, and innovation stakeholders to strengthen Brazil’s position in the global market. 

At the conference, LSN’s CEO, Dennis Ford, delivered a masterclass on running global fundraising campaigns and building two-way innovation bridges between regional science and global capital. This was followed by a panel discussion, “Where Brazil Is and Where We Should Aim Towards,” featuring KX Ventures, IKJ, Sebrae, Ganesha Labs, and Life Science Nation, and moderated by Marcos Valadares of ABIQUIFI. 

Over several days surrounding the conference, ApexBrasil and ABIQUIFI facilitated a series of high-level introductions that connected LSN and Ganesha Labs with leaders from accelerators, investment groups, and research institutions across Brazil. These discussions focused on aligning Brazil’s growing innovation infrastructure with global commercialization frameworks and investor networks. 

The São Paulo visit capped two years of collaboration between the organizations, during which ApexBrasil and ABIQUIFI have sent multiple cohorts of Brazilian life-science companies to LSN’s Redefining Every Stage of Investment JPM events and LSN Labs training programs. 

Together, they have provided Brazilian entrepreneurs with a structured path to international investors and licensing partners, and a deeper understanding of how to prepare and execute a global fundraising campaign. 

This ongoing collaboration is laying the groundwork for Brazil to become a formal anchor node in the LSN Global Partnering Ecosystem. This worldwide network links regional innovation hubs to global capital and corporate partners. Through continued coordination, the parties aim to establish a lasting two-way innovation bridge between Brazil and LSN’s international ecosystem, enabling Brazilian technologies to access global markets while channeling international investors and strategic partners into the country’s rapidly expanding life-science sector. 

According to Dennis Ford, Founder and CEO of Life Science Nation, 

“Brazil’s scientific depth and entrepreneurial momentum make it one of the most exciting emerging markets in life sciences. ApexBrasil and ABIQUIFI are doing exactly what global investors want to see—creating a coordinated pathway that connects local innovation with international capital and commercialization opportunities. LSN is proud to help Brazil take this next step.” 

Norberto Prestes, CEO of ABIQUIFI, emphasized the export and funding side of the bridge: 

“Brazil has a rich foundation of science and talent. Our goal is to help these innovations secure the visibility, funding, and partnerships they need to reach international markets. The collaboration with LSN provides the structure and access needed to make that happen.” 

Debora Lima of ApexBrasil highlighted the importance of bringing international investors into the Brazilian ecosystem: 

“Our mission is to connect Brazil with the world—to bring investors, partners, and collaborators to see firsthand the innovation emerging here. Working with LSN allows us to open new channels for global capital to engage directly with Brazilian startups and research institutions.” 

About Life Science Nation

Life Science Nation (LSN) is a global matching and partnering engine that connects early-stage life-science companies with investors and licensing partners through its integrated ecosystem—including the LSN Investor & Licensing Partner Database, the RESI Conference Series, and LSN Labs Accelerator. LSN has supported more than 400 companies in raising over $5 billion in verified funding worldwide.

About ApexBrasil

ApexBrasil promotes Brazilian products and services abroad and attracts foreign investment to strategic sectors of the Brazilian economy, strengthening national competitiveness and international presence.

About ABIQUIFI

ABIQUIFI represents the Brazilian Pharmaceutical Inputs Industry, advancing innovation, quality, and competitiveness across the national health and life-sciences sector.

Registration now open:

  • RESI London 2025 (Dec. 4, 8&9) – [Register]
  • RESI JPM 2026 (Jan.12-14, 19&20)– [Register]
  • RESI Europe 2026 (March 23-25) – [Register]

Tags: , , , , , , , , , , ,

Kobe Biomedical Innovation Cluster (KBIC) Joins RESI JPM 2026 as Gold Sponsor

28 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is proud to announce that the Kobe Biomedical Innovation Cluster (KBIC) will serve as a sponsor for RESI JPM 2026, continuing its mission to promote innovation, entrepreneurship, and global collaboration in life sciences. 

As part of this sponsorship, KBIC will host the Kansai Life Sciences Accelerator Program (KLSAP) 2025 Demo Day at RESI JPM 2026 on Tuesday, January 13, 12:00 – 2:00pm PT at the Marriott Marquis San Francisco. The Demo Day will feature 3 startups that are part of the KLSAP 2025 Cohort as well as other member companies of KBIC, to be announced as the event approaches. This initiative will provide participating companies with global exposure, strategic investor connections, and the opportunity to pitch to an international audience of early-stage investors and strategic partners across life science and healthcare sectors.

Interested in joining and receiving updates on the KLSAP 2025 Demo Day? Please contact Claire Jeong, VP of Investor Research, Asia BD, at c.jeong@lifesciencenation.com.  

Introduction of Kobe Biomedical Innovation Cluster (KBIC)
Located in the heart of Kobe, Japan, the Kobe Biomedical Innovation Cluster is one of the nation’s leading ecosystems dedicated to the advancement of biomedical research and commercialization. With more than 340 organizations, including research institutes, hospitals, and life science companies, KBIC plays a vital role in bridging academia, government, and industry to accelerate innovation and improve global health outcomes. 

By partnering with RESI JPM 2026, KBIC aims to strengthen international collaboration and support Japanese startups seeking to expand their networks and raise global awareness for their technologies. Through this continued engagement, KBIC and LSN will work together help founders access global capital and strategic resources to advance from concept to commercialization. 

About Kansai Life Sciences Accelerator Program (KLSAP)
Powered by KBIC, the Kansai Life Sciences Accelerator Program (KLSAP) supports early-stage life science and healthcare startups in the Kansai region through tailored mentorship, commercialization guidance, and access to global investor networks. 

The 2025 KLSAP Cohort will participate in RESI JPM 2026 to present their innovations to a diverse investor audience, gain valuable feedback, and establish partnerships that can help drive their technologies toward global markets. The cohort’s participation exemplifies KBIC’s commitment to supporting international expansion and facilitating cross-border collaboration in life sciences. 3 companies have been selected for this year’s KLSAP Cohort, with descriptions of each company added below:

C-Biomex
Founded in 2017, C-Biomex is a bio-venture dedicated to advancing novel theranostics using its proprietary peptide discovery platform, CUS™. The platform enables identification of peptides with high stability and specificity through a three-step process involving a high-purity library, an innovative screening protocol that minimizes background interactions, and direct sequencing via a proprietary algorithm. C-Biomex focuses on radiopharmaceutical development, positioning itself at the intersection of diagnostics and therapeutics to accelerate peptide-based solutions for global biomedical applications.

GeneMedicine
GeneMedicine, founded in 2014 and based in Seoul, develops oncolytic viruses engineered to selectively replicate in and kill cancer cells while stimulating an anti-tumor immune response. Its GM-oAd platform is designed for systemic delivery of oncolytic adenoviruses with enhanced tumor specificity, immune activation, and ability to overcome physical tumor barriers. In addition to its therapeutic pipeline, GeneMedicine is expanding into CDMO services and novel drug-delivery systems, building a sustainable and diversified business model.

iXgene
iXgene is a Japanese life sciences company focused on developing therapies for intractable diseases using genome editing and induced pluripotent stem (iPS) cell technology. Its proprietary platform combines advanced genome editing tools, such as CRISPR, with iPS-derived therapeutics targeting indications including malignant brain tumors and brain injury. iXgene collaborates with academic institutions and pharmaceutical partners to translate next-generation regenerative and gene therapies into the clinic, aiming to address high-unmet-need central nervous system diseases. 

LSN and KBIC invites all investors, industry leaders, and innovators to meet the KLSAP 2025 Cohort at RESI JPM 2026. Together, they will continue to advance global innovation and foster meaningful connections across the life sciences ecosystem. 

Register for RESI JPM

Tags: , , , , , , , , , ,

Hot Investor Mandate: Angel Syndicate Targets Investments Into Life Science Tools, Software, and Platform Technologies Across Pre-Seed to Series A

28 Oct

An angel syndicate is focused on life science tools and biotech infrastructure. The firm has a concentrated investment strategy targeting U.S.-based companies from the Pre-Seed to Series A stages. The firm’s investor base includes a select group of limited partners, about half of whom are active operators within the life science tools sector. The firm can co-invest but prefers to lead investments, with typical check sizes ranging from $160K to $2M. The firm brings deep domain expertise in life sciences and works closely with founders to build companies, pairing them with strategic capital. The firm is thesis-driven and leverages its extensive operator network, commercial reach, and M&A experience to accelerate company growth and strategy. The firm supports all aspects of business development, from financial modeling and strategic planning to connecting founders with key industry stakeholders within the life sciences ecosystem. 

The firm exclusively targets life science tools, software, biotech infrastructure, and platform technologies that typically include a consumable component. The firm does not invest in therapeutics, diagnostics, digital health, or any business requiring FDA clearance. The firm is open to all development stages and all classes of tools, software, and platform technologies. 

The firm only works with companies whose founders and teams are fully dedicated to their ventures. The firm generally prefers to take a board seat if it leads the investment round and if doing so aligns with the company’s stage of development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Western Europe-Based VC Firm Focuses on Medtech and Digital Health Investments Across the Globe

28 Oct

Founded in 2021, an early-stage venture capital firm based in Western Europe invests in multiple verticals. Within life science and healthcare, the firm focuses on medtech and digital health. The sweet point for the firm is pre-seed. Initial investment is typically around €600K, with the potential for follow-on investment of another €600K Euro. The firm is open to opportunities globally with no geographical restrictions. While the firm is open to both leading and co-investing in rounds, the firm would prefer if there is a lead investor in place. 
 
Within life science and healthcare, the firm is focused on medtech and digital health, and is opportunistic in subsectors and indications. Some areas of interest are: surgical devices and cardiovascular diseases. For the stage of development, the firm is open to investing in the preclinical stage, but would prefer companies that have prototypes. 
 
There is no specific requirement for the company’s management team. The firm is interested in working with experienced entrepreneurs. The firm is an active investor and will consider observer seats on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Global Investment Firm Seeks Novel Cell & Gene Therapies in Pre-Clinical and Early Clinical Stage, Investing Up to $10M

28 Oct

An investment firm based in the Middle East is a premier investment company with a diverse portfolio spanning multiple asset classes, including real assets and alternative investments. The firm’s vision is to become a leading integrated solutions provider in cell and gene therapy, establishing itself as the first globally trusted partner in precision medicine within the Middle East. The firm focuses on providing research, manufacturing, and a comprehensive range of services related to genomic medicine, targeting local, regional, and international markets. Check sizes vary and are flexible but on average range between USD $5–10M. In alignment with national strategic initiatives, the firm aims to act as a catalyst for developing this vital industry and emphasizes the importance of the private sector in supporting emerging, innovative sectors. The firm aspires to accelerate the delivery of groundbreaking innovations and ensure patient access to treatments for chronic and rare diseases while contributing to the localization of the biotechnology industry and building national expertise to achieve these ambitious goals. 

Within therapeutics, the firm is focused on cell and gene therapy in IND, Phase 1, and/or moving into Phase 2. There are several indications of interest, including orphan diseases, oncology, neurology, immunology, cardiovascular diseases, and diabetes. For tech-driven biosciences, the firm is interested in AI-driven platforms for drug discovery and clinical development. 

The firm is only interested in companies willing to work toward the goal of bringing biotech innovation to the region through manufacturing and clinical development. A carve-out or partnership in the region is necessary. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →